Trial Information
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients
Inclusion Criteria:
- Scheduled to receive nonmyeloablative conditioning which includes fludarabine
- Scheduled to receive a haploidentical graft
- Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate
mofetil (MMF) or enteric-coated mycophenolic acid
- Age >18 years at the time of enrollment
Exclusion Criteria:
- Diagnosed with an immunodeficiency disorder, including HIV
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Donor T-cell chimerism
Outcome Time Frame:
Day 28 post-transplant
Safety Issue:
No
Principal Investigator
Jeannine McCune, PharmD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Fred Hutchinson Cancer Research Center
Authority:
United States: Institutional Review Board
Study ID:
FHCRC-2373.00
NCT ID:
NCT01141959
Start Date:
May 2010
Completion Date:
December 2011
Related Keywords:
- Leukemia
- Hodgkin Disease
- Non-Hodgkin Lymphoma
- Myelodysplastic Syndrome
- Multiple Myeloma
- hematopoietic stem cell transplantation
- cyclophosphamide
- fludarabine
- mycophenolate mofetil
- mycophenolic acid
- biomarkers
- Hodgkin Disease
- Leukemia
- Lymphoma
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Myelodysplastic Syndromes
- Preleukemia
Name | Location |
Fred Hutchinson Cancer Research Center |
Seattle, Washington 98109 |